+ More
Technology
Collaborations
 News Room
 Contact Us
Home \ + More \ Newsroom

News & Events

NEW Published Data Shows Feasibility of GlySens ICGM System
RESEARCH ARTICLE | JY Lucisano et al. "Glucose Monitoring in Individuals With Diabetes Using a Long-Term Implanted Sensor/Telemetry System and Model" Transactions on Biomedical Engineering, September 2017: Vol. 64, No 9, DOI: 10.1109/TBME.2016. 2619333
SAN DIEGO, CA – January 3, 2017 – GlySens® Incorporated today announced the publication of new data in Transactions on Biomedical Engineering, from the development of the ICGM® System; intended for long-term monitoring of subcutaneous tissue glucose in people with diabetes. The ICGM System data closely matched reference blood glucose and finger stick values from all participants. Statistical correlation indicated strong association between the sensor signals and reference glucose values. Therefore long-term glucose monitoring in individuals with diabetes is shown to be feasible with this system and further development continues...
Read More>

2016

GlySens Incorporated Shares Recent Data and Market Insights of the Long Term, Fully Implantable Glucose Monitoring System
BETHESDA, MD – November 10, 2016– GlySens Incorporated executives, Bill Markle and Joseph Lucisano, PhD presented separate findings at the 16th annual Diabetes Technology Society meeting. This conference brings together leading scientific researchers and health care professionals from around the world to focus on applying science and new technologies to the fight against diabetes. The presentation entitled “Market Opportunities and Customer Preference Data for a Fully Implanted...
Read More>
Patient Enrollment and Implantation Procedures Complete for FIGS-2 Trial
SAN DIEGO, CA - October 4, 2016  – GlySens Incorporated today announced the successful implantation of the twentieth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long-term assessment of the Eclipse® ICGM® Sensor. The twentieth participant is an important milestone for the company. “We believe the clinical data will further support our growing confidence...
Read More>
Event
GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at 4th Annual NIH Artificial Pancreas Workshop Patient Enrollment and Implantation Procedures Complete for FIGS-2 Trial
BETHESDA, MD - July 6, 2016  – GlySens Incorporated’s presentation entitled “Continuous, Long-term, Fully Implanted Glucose Sensor” was discussed today by Dr. Joseph Lucisano, the Company’s founder and CTO, at the “Fourth Artificial Pancreas Workshop.” This event, held at the National Institutes of Health (NIH) campus, is organized in coordination with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Diabetes Mellitus Interagency Coordinating Committee (DIMCC). The ...
Read More>
Successful Re-implantation of the Eclipse® ICGM® Sensor in Sixth Clinical Trial Participant
SAN DIEGO, CA - March 14, 2016 – GlySens Incorporated today completed the successful re-implantation of the Eclipse® ICGM® Sensor in a sixth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long- term assessment of the Eclipse ICGM Sensor.
Read More>
GlySens Incorporated Secures $20M Series D Investment to Advance its Fully Implanted, Long-Term Continuous Glucose Monitoring System
SAN DIEGO, CA - January 5, 2016 /PRNewswire/ – GlySens Incorporated announced today that it has closed a $20M Series D financing led by prior investors from its Series C round, in addition to significant participation from new investors.
“The clinical performance of our fully implanted ICGM® system, now with multiple patients approaching 12 months of in-vivo use, was instrumental in our ability to secure incremental funding on terms highly supportive of the Company’s long term vision and...
Read More>
3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121
Ph:  +1 (858) 638-7708
Fax: +1 (858) 638-7727

TechnologyNews RoomCareersContact Us

© 2018 GlySens Incorporated. All Rights Reserved.
Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
GlySens®, Eclipse®, and ICGM® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
 Terms of Use Privacy Policy
map-markercalendarcogsphonelinkedinslidesharenewspaper-omenubook